Invest in InvVax

We use a new genetics platform to develop better vaccines for flu, COVID-19, etc

EARLY BIRD TERMS: $77,387 LEFT

$122,613

raised from 122 investors
INVESTMENT TERMS
Convertible Note
 $10M  $7.5M valuation cap
Early Bird Bonus: The first $200K of investments will be in a convertible note with a $7.5M valuation cap and 35% discount

Highlights

1
Huge global market for these vaccines: Universal flu - $22B; COVID-19 - $5B
2
Chance to make an enormous societal impact
3
Patented durable and universal flu vaccine
4
Major smashes: Moderna, BioNTech, Novavax: Invest in the next one!

Featured Investor

Our Team


*To our knowledge, this is the only universal flu vaccine targeting invariant sequence of influenza, but there could be, in theory, others that we do not know about.

Source: Vision Research Reports.

To our knowledge, we are the only company focused on invariance. There could be others we do not know about.

Forward-looking projections are not guaranteed.

Forward-looking projections are not guaranteed.

Overview